Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 6/27/24 → 6/27/26 |
Funding
- Merck Sharp & Dohme Corporation: $12,580.00
24-GI-134-MSD (015-00):A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma,Gastroesoph
- Patel, Reema (PI)